{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:22:26Z","timestamp":1792092146128,"version":"4.4.0"},"reference-count":260,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"DOI":"10.1186\/s13046-026-03762-y","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:38:50Z","timestamp":1781771930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cellular immunotherapy in melanoma: the next frontier in cancer treatment"],"prefix":"10.1186","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9781-1963","authenticated-orcid":false,"given":"Anna-Lena","family":"Wien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-8087","authenticated-orcid":false,"given":"Angeliki","family":"Stamtsis-Datsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"3762_CR1","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today.; 2024 [cited 2025 Dec 27]. Available from: URL: https:\/\/gco.iarc.who.int\/today."},{"issue":"2","key":"3762_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CM9.0000000000003416","volume":"138","author":"M Wang","year":"2025","unstructured":"Wang M, Gao X, Zhang L. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chin Med J (Engl). 2025;138(2):185\u201392. https:\/\/doi.org\/10.1097\/CM9.0000000000003416.","journal-title":"Chin Med J (Engl)"},{"key":"3762_CR3","doi-asserted-by":"publisher","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiol Melanoma Med Sci (Basel) 2021;9(4):63. https:\/\/doi.org\/10.3390\/medsci904006.","DOI":"10.3390\/medsci904006"},{"issue":"8","key":"3762_CR4","first-page":"739","volume":"5","author":"M Mihajlovic","year":"2012","unstructured":"Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol. 2012;5(8):739\u201353.","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"3762_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic Classif Cutan Melanoma Cell. 2015;161(7):1681\u201396. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044.","journal-title":"Genomic Classif Cutan Melanoma Cell"},{"issue":"6","key":"3762_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ijc.35463","volume":"157","author":"O Langselius","year":"2025","unstructured":"Langselius O, Rumgay H, de Vries E, Whiteman DC, Jemal A, Parkin DM, et al. Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation in 2022. Int J Cancer. 2025;157(6):1110\u20139. https:\/\/doi.org\/10.1002\/ijc.35463.","journal-title":"Int J Cancer"},{"issue":"2","key":"3762_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017;32(2):204\u2013e22015. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.003.","journal-title":"Cancer Cell"},{"issue":"1","key":"3762_CR8","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163. https:\/\/doi.org\/10.1038\/s41467-019-11107-x.","journal-title":"Nat Commun"},{"issue":"8","key":"3762_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775\u201384. https:\/\/doi.org\/10.1080\/14737140.2018.1489246.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3762_CR10","doi-asserted-by":"crossref","unstructured":"Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2025; 36(1):10\u201330. Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/39550033\/.","DOI":"10.1016\/j.annonc.2024.11.006"},{"issue":"1","key":"3762_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2.","journal-title":"Mol Cancer"},{"issue":"12","key":"3762_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Annals oncology: official J Eur Soc Med Oncol. 2024;35(12):1191\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2330.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"6382","key":"3762_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"issue":"1","key":"3762_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"issue":"13","key":"3762_CR15","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1200\/JCO.24.01124","volume":"43","author":"HA Tawbi","year":"2025","unstructured":"Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol. 2025;43(13):1546\u201352. https:\/\/doi.org\/10.1200\/JCO.24.01124.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3762_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"issue":"36","key":"3762_CR17","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol. 2022;40(36):4178\u201388. https:\/\/doi.org\/10.1200\/JCO.23.00385.","journal-title":"J Clin Oncol"},{"key":"3762_CR18","doi-asserted-by":"publisher","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","volume":"215","author":"C Garbe","year":"2025","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. Eur J Cancer. 2025;215:115153. https:\/\/doi.org\/10.1016\/j.ejca.2024.115153.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3762_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong T-G, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763.","journal-title":"J Clin Oncol"},{"key":"3762_CR20","doi-asserted-by":"publisher","unstructured":"Amaral T, Seeber O, Mersi E, Sanchez S, Thomas I, Meiwes A et al. Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma. Cancers (Basel). 2020;12(4):1027. https:\/\/doi.org\/10.3390\/cancers12041027.","DOI":"10.3390\/cancers12041027"},{"issue":"1","key":"3762_CR21","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","volume":"14","author":"SY Lim","year":"2023","unstructured":"Lim SY, Shklovskaya E, Lee JH, Pedersen B, Stewart A, Ming Z, et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2023;14(1):1516. https:\/\/doi.org\/10.1038\/s41467-023-36979-y.","journal-title":"Nat Commun"},{"issue":"14","key":"3762_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377(14):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"key":"3762_CR23","doi-asserted-by":"publisher","unstructured":"Fateeva A, Eddy K, Chen S. Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance. Cancers (Basel). 2024;16(8):1571. https:\/\/doi.org\/10.3390\/cancers16081571.","DOI":"10.3390\/cancers16081571"},{"issue":"5","key":"3762_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41435-024-00299-y","volume":"25","author":"A Datsi","year":"2024","unstructured":"Datsi A, Sorg RV, Garg AD. The conundrum of CD8\u2009+\u2009T cell trajectories in low antigenic tumors: How to overcome a hypofunctional state distinct from antigen-driven exhaustion? Genes Immun. 2024;25(5):353\u20135. https:\/\/doi.org\/10.1038\/s41435-024-00299-y.","journal-title":"Genes Immun"},{"issue":"6","key":"3762_CR25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","volume":"24","author":"TN Gide","year":"2018","unstructured":"Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res. 2018;24(6):1260\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2267.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3762_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24(1):20. https:\/\/doi.org\/10.1186\/s12943-024-02212-7.","journal-title":"Mol Cancer"},{"key":"3762_CR27","doi-asserted-by":"publisher","unstructured":"Zieli\u0144ska MK, Ci\u0105\u017cy\u0144ska M, Sulejczak D, Rutkowski P, Czarnecka AM. Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It. Biomolecules. 2025;15(2):269. https:\/\/doi.org\/10.3390\/biom15020269.","DOI":"10.3390\/biom15020269"},{"key":"3762_CR28","doi-asserted-by":"publisher","first-page":"102499","DOI":"10.1016\/j.ctrv.2022.102499","volume":"113","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Koutouratsas T, Haanen J, Gogas H. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome? Cancer Treat Rev. 2023;113:102499. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102499.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"3762_CR29","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1001\/jamaoncol.2020.4401","volume":"6","author":"R Dummer","year":"2020","unstructured":"Dummer R, Ascierto PA, Nathan P, Robert C, Schadendorf D. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. JAMA Oncol. 2020;6(12):1957\u201366. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4401.","journal-title":"JAMA Oncol"},{"key":"3762_CR30","doi-asserted-by":"publisher","first-page":"1665488","DOI":"10.3389\/fimmu.2025.1665488","volume":"16","author":"J Qian","year":"2025","unstructured":"Qian J, Liu Y. Recent advances in adoptive cell therapy for cancer immunotherapy. Front Immunol. 2025;16:1665488. https:\/\/doi.org\/10.3389\/fimmu.2025.1665488.","journal-title":"Front Immunol"},{"key":"3762_CR31","doi-asserted-by":"publisher","unstructured":"Filin IY, Mayasin YP, Kharisova CB, Gorodilova AV, Kitaeva KV, Chulpanova DS, et al. Cell Immunotherapy against Melanoma: Clinical Trials Review. Int J Mol Sci. 2023;24(3):2413. https:\/\/doi.org\/10.3390\/ijms24032413.","DOI":"10.3390\/ijms24032413"},{"issue":"3","key":"3762_CR32","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nm0398-328","volume":"4","author":"FO Nestle","year":"1998","unstructured":"Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328\u201332. https:\/\/doi.org\/10.1038\/nm0398-328.","journal-title":"Nat Med"},{"issue":"4","key":"3762_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2217\/mmt-2016-0014","volume":"3","author":"RO Dillman","year":"2016","unstructured":"Dillman RO, Nistor GI, Cornforth AN. Dendritic cell vaccines for melanoma: past, present and future. Melanoma Manag. 2016;3(4):273\u201389. https:\/\/doi.org\/10.2217\/mmt-2016-0014.","journal-title":"Melanoma Manag"},{"key":"3762_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.mcb.2023.05.007","volume":"183","author":"A Datsi","year":"2024","unstructured":"Datsi A, Falkowski L, Sorg RV. Generation and quality control of mature monocyte-derived dendritic cells for immunotherapy. Methods Cell Biol. 2024;183:1\u201331. https:\/\/doi.org\/10.1016\/bs.mcb.2023.05.007.","journal-title":"Methods Cell Biol"},{"key":"3762_CR35","doi-asserted-by":"publisher","unstructured":"Zhang S, Mo S, Huang W, Zhong D, Yang X, Xie S, et al. Dendritic cell vaccines: Current research progress, challenges, and opportunities. Genes Dis. 2025;13(4):101913. https:\/\/doi.org\/10.1016\/j.gendis.2025.101913.","DOI":"10.1016\/j.gendis.2025.101913"},{"key":"3762_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1479-5876-8-89","volume":"8","author":"A Ribas","year":"2010","unstructured":"Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010;8:89. https:\/\/doi.org\/10.1186\/1479-5876-8-89.","journal-title":"J Transl Med"},{"issue":"1","key":"3762_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12967-025-06403-8","volume":"23","author":"J Bulgarelli","year":"2025","unstructured":"Bulgarelli J, Piccinini C, Scarpi E, Gentili G, Renzi L, Carloni S, et al. Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial. J Transl Med. 2025;23(1):455. https:\/\/doi.org\/10.1186\/s12967-025-06403-8.","journal-title":"J Transl Med"},{"issue":"1","key":"3762_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1479-5876-3-4","volume":"3","author":"Y Akiyama","year":"2005","unstructured":"Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, et al. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med. 2005;3(1):4. https:\/\/doi.org\/10.1186\/1479-5876-3-4.","journal-title":"J Transl Med"},{"issue":"7","key":"3762_CR39","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00262-007-0435-8","volume":"57","author":"P Hersey","year":"2008","unstructured":"Hersey P, Halliday GM, Farrelly ML, DeSilva C, Lett M, Menzies SW. Phase I\/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother. 2008;57(7):1039\u201351. https:\/\/doi.org\/10.1007\/s00262-007-0435-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3762_CR40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/annonc\/mdj138","volume":"17","author":"D Schadendorf","year":"2006","unstructured":"Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Br\u00f6cker E-B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Annals oncology: official J Eur Soc Med Oncol. 2006;17(4):563\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdj138.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"3762_CR41","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3389\/fimmu.2017.01594","volume":"8","author":"KM Hargadon","year":"2017","unstructured":"Hargadon KM. Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma. Front Immunol. 2017;8:1594. https:\/\/doi.org\/10.3389\/fimmu.2017.01594.","journal-title":"Front Immunol"},{"issue":"4","key":"3762_CR42","doi-asserted-by":"publisher","first-page":"e1560919","DOI":"10.1080\/2162402X.2018.1560919","volume":"8","author":"C Rabu","year":"2019","unstructured":"Rabu C, Rangan L, Florenceau L, Fortun A, Charpentier M, Dupr\u00e9 E, et al. Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells. OncoImmunology. 2019;8(4):e1560919. https:\/\/doi.org\/10.1080\/2162402X.2018.1560919.","journal-title":"OncoImmunology"},{"issue":"13","key":"3762_CR43","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.7150\/thno.38742","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Yang J, Wang L, Liu B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics. 2020;10(13):6011\u201323. https:\/\/doi.org\/10.7150\/thno.38742.","journal-title":"Theranostics"},{"issue":"10","key":"3762_CR44","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/eji.201343324","volume":"43","author":"RA Rosalia","year":"2013","unstructured":"Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol. 2013;43(10):2554\u201365. https:\/\/doi.org\/10.1002\/eji.201343324.","journal-title":"Eur J Immunol"},{"issue":"6236","key":"3762_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803\u20138. https:\/\/doi.org\/10.1126\/science.aaa3828.","journal-title":"Science"},{"issue":"7","key":"3762_CR46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00262-005-0078-6","volume":"55","author":"M Salcedo","year":"2006","unstructured":"Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006;55(7):819\u201329. https:\/\/doi.org\/10.1007\/s00262-005-0078-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3762_CR47","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","volume":"15","author":"KF Bol","year":"2024","unstructured":"Bol KF, Schreibelt G, Bloemendal M, van Willigen WW, Hins-de Bree S, de Goede AL, et al. Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial. Nat Commun. 2024;15(1):1632. https:\/\/doi.org\/10.1038\/s41467-024-45358-0.","journal-title":"Nat Commun"},{"issue":"1","key":"3762_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/bjc.2011.538","volume":"106","author":"SJ Win","year":"2012","unstructured":"Win SJ, McMillan DGG, Errington-Mais F, Ward VK, Young SL, Baird MA, et al. Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles. Br J Cancer. 2012;106(1):92\u20138. https:\/\/doi.org\/10.1038\/bjc.2011.538.","journal-title":"Br J Cancer"},{"key":"3762_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2018.01.004","volume":"272","author":"M Zhu","year":"2018","unstructured":"Zhu M, Ding X, Zhao R, Liu X, Shen H, Cai C, et al. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma. J Control Release. 2018;272:72\u201382. https:\/\/doi.org\/10.1016\/j.jconrel.2018.01.004.","journal-title":"J Control Release"},{"issue":"1","key":"3762_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/1479-5876-9-223","volume":"9","author":"J Fu\u010d\u00edkov\u00e1","year":"2011","unstructured":"Fu\u010d\u00edkov\u00e1 J, Ro\u017ekov\u00e1 D, Ul\u010dov\u00e1 H, Budinsk\u00fd V, Sochorov\u00e1 K, Pokorn\u00e1 K, et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med. 2011;9(1):223. https:\/\/doi.org\/10.1186\/1479-5876-9-223.","journal-title":"J Transl Med"},{"issue":"9","key":"3762_CR51","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1471-4906(02)02281-0","volume":"23","author":"MB Lutz","year":"2002","unstructured":"Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002;23(9):445\u20139. https:\/\/doi.org\/10.1016\/s1471-4906(02)02281-0.","journal-title":"Trends Immunol"},{"issue":"11","key":"3762_CR52","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00262-008-0489-2","volume":"57","author":"ACI Boullart","year":"2008","unstructured":"Boullart ACI, Aarntzen EHJG, Verdijk P, Jacobs JFM, Schuurhuis DH, Benitez-Ribas D, et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7\/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother. 2008;57(11):1589\u201397. https:\/\/doi.org\/10.1007\/s00262-008-0489-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"3762_CR53","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","volume":"64","author":"RB Mailliard","year":"2004","unstructured":"Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64(17):5934\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1261.","journal-title":"Cancer Res"},{"issue":"8","key":"3762_CR54","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00262-008-0648-5","volume":"58","author":"AS Giermasz","year":"2009","unstructured":"Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009;58(8):1329\u201336. https:\/\/doi.org\/10.1007\/s00262-008-0648-5.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"3762_CR55","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/mt.2008.77","volume":"16","author":"A Bonehill","year":"2008","unstructured":"Bonehill A, Tuyaerts S, van Nuffel AMT, Heirman C, Bos TJ, Fostier K, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16(6):1170\u201380. https:\/\/doi.org\/10.1038\/mt.2008.77.","journal-title":"Mol Ther"},{"issue":"10","key":"3762_CR56","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","volume":"24","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, van Nuffel AMT, Benteyn D, Corthals J, Aerts C, Heirman C, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Annals oncology: official J Eur Soc Med Oncol. 2013;24(10):2686\u201393. https:\/\/doi.org\/10.1093\/annonc\/mdt245.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"12","key":"3762_CR57","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","volume":"34","author":"S Wilgenhof","year":"2016","unstructured":"Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, et al. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. JCO. 2016;34(12):1330\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.63.4121.","journal-title":"JCO"},{"issue":"7","key":"3762_CR58","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-08-2729","volume":"15","author":"P Verdijk","year":"2009","unstructured":"Verdijk P, Aarntzen EHJG, Lesterhuis WJ, Boullart ACI, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009;15(7):2531\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2729.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"3762_CR59","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1200\/JCO.2003.04.042","volume":"21","author":"I Bedrosian","year":"2003","unstructured":"Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8\u2009+\u2009T-cell function in melanoma patients. JCO. 2003;21(20):3826\u201335. https:\/\/doi.org\/10.1200\/JCO.2003.04.042.","journal-title":"JCO"},{"issue":"17","key":"3762_CR60","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1158\/1078-0432.CCR-11-1261","volume":"17","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, de Vries IJM, Schreibelt G, Lambeck AJA, Aarntzen EHJG, Jacobs JFM, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res. 2011;17(17):5725\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1261.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3762_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-008-0568-4","volume":"58","author":"L Engell-Noerregaard","year":"2009","unstructured":"Engell-Noerregaard L, Hansen TH, Andersen MH, thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58(1):1\u201314. https:\/\/doi.org\/10.1007\/s00262-008-0568-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"3762_CR62","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","volume":"190","author":"B Thurner","year":"1999","unstructured":"Thurner B, Haendle I, R\u00f6der C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190(11):1669\u201378. https:\/\/doi.org\/10.1084\/jem.190.11.1669.","journal-title":"J Exp Med"},{"issue":"10","key":"3762_CR63","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00262-005-0106-6","volume":"55","author":"JW Fay","year":"2006","unstructured":"Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother. 2006;55(10):1209\u201318. https:\/\/doi.org\/10.1007\/s00262-005-0106-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3762_CR64","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3892\/or.2012.1956","volume":"28","author":"C Oshita","year":"2012","unstructured":"Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep. 2012;28(4):1131\u20138. https:\/\/doi.org\/10.3892\/or.2012.1956.","journal-title":"Oncol Rep"},{"issue":"22","key":"3762_CR65","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1012863.","journal-title":"N Engl J Med"},{"issue":"10","key":"3762_CR66","doi-asserted-by":"publisher","first-page":"e1216290","DOI":"10.1080\/2162402X.2016.1216290","volume":"5","author":"P Baumgaertner","year":"2016","unstructured":"Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, et al. Vaccination of stage III\/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8\u2009+\u2009and CD4\u2009+\u2009T-cell responses with multiple specificities including a novel DR7-restricted epitope. OncoImmunology. 2016;5(10):e1216290. https:\/\/doi.org\/10.1080\/2162402X.2016.1216290.","journal-title":"OncoImmunology"},{"issue":"9","key":"3762_CR67","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/ijc.70006","volume":"157","author":"EK Ninmer","year":"2025","unstructured":"Ninmer EK, Zhu H, Chianese-Bullock KA, Slingluff CL. Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial. Int J Cancer. 2025;157(9):1912\u201323. https:\/\/doi.org\/10.1002\/ijc.70006.","journal-title":"Int J Cancer"},{"issue":"1","key":"3762_CR68","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41467-024-46877-6","volume":"15","author":"EK Ninmer","year":"2024","unstructured":"Ninmer EK, Zhu H, Chianese-Bullock KA, von Mehren M, Haas NB, Ross MI, et al. Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial. Nat Commun. 2024;15(1):2570. https:\/\/doi.org\/10.1038\/s41467-024-46877-6.","journal-title":"Nat Commun"},{"issue":"1","key":"3762_CR69","doi-asserted-by":"publisher","first-page":"14661","DOI":"10.1038\/s41598-021-94250-0","volume":"11","author":"M Yazdani","year":"2021","unstructured":"Yazdani M, Gholizadeh Z, Nikpoor AR, Mohamadian Roshan N, Jaafari MR, Badiee A. Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy. Sci Rep. 2021;11(1):14661. https:\/\/doi.org\/10.1038\/s41598-021-94250-0.","journal-title":"Sci Rep"},{"issue":"7","key":"3762_CR70","doi-asserted-by":"publisher","first-page":"e1445457","DOI":"10.1080\/2162402X.2018.1445457","volume":"7","author":"M Grees","year":"2018","unstructured":"Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, et al. Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. OncoImmunology. 2018;7(7):e1445457. https:\/\/doi.org\/10.1080\/2162402X.2018.1445457.","journal-title":"OncoImmunology"},{"issue":"10","key":"3762_CR71","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00262-014-1575-2","volume":"63","author":"I Poschke","year":"2014","unstructured":"Poschke I, L\u00f6vgren T, Adamson L, Nystr\u00f6m M, Andersson E, Hansson J, et al. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother. 2014;63(10):1061\u201371. https:\/\/doi.org\/10.1007\/s00262-014-1575-2.","journal-title":"Cancer Immunol Immunother"},{"key":"3762_CR72","doi-asserted-by":"publisher","unstructured":"Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget M-A et al. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021;9(5):e002449. https:\/\/doi.org\/10.1136\/jitc-2021-002449.","DOI":"10.1136\/jitc-2021-002449"},{"issue":"10","key":"3762_CR73","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00262-012-1242-4","volume":"61","author":"E Ellebaek","year":"2012","unstructured":"Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother. 2012;61(10):1791\u2013804. https:\/\/doi.org\/10.1007\/s00262-012-1242-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3762_CR74","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","volume":"6","author":"MW Rohaan","year":"2018","unstructured":"Rohaan MW, van den Berg JH, Kvistborg P, Haanen JBAG. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer. 2018;36(1):102. https:\/\/doi.org\/10.1186\/s40425-018-0391-1.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3762_CR75","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","volume":"21","author":"SA Rosenberg","year":"2009","unstructured":"Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233\u201340. https:\/\/doi.org\/10.1016\/j.coi.2009.03.002.","journal-title":"Curr Opin Immunol"},{"key":"3762_CR76","doi-asserted-by":"publisher","unstructured":"Kristensen NP, Heeke C, Tvingsholm SA, Borch A, Draghi A, Crowther MD et al. Neoantigen-reactive CD8\u2009+\u2009T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J Clin Invest. 2022;18;132(2):e150535. https:\/\/doi.org\/10.1172\/JCI150535.132(2).","DOI":"10.1172\/JCI150535.132(2)"},{"issue":"25","key":"3762_CR77","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u201380. https:\/\/doi.org\/10.1056\/NEJM198812223192527.","journal-title":"N Engl J Med"},{"issue":"12","key":"3762_CR78","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","volume":"30","author":"U Dafni","year":"2019","unstructured":"Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals oncology: official J Eur Soc Med Oncol. 2019;30(12):1902\u201313. https:\/\/doi.org\/10.1093\/annonc\/mdz398.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"13","key":"3762_CR79","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0116.","journal-title":"Clin Cancer Res"},{"key":"3762_CR80","doi-asserted-by":"publisher","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;Dec;10(12):e005755. https:\/\/doi.org\/10.1136\/jitc-2022-005755.10(12).","DOI":"10.1136\/jitc-2022-005755.10(12)"},{"issue":"19","key":"3762_CR81","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","volume":"31","author":"L Hu","year":"2025","unstructured":"Hu L, Fan C, Bross P, Das A, Cho ES, Knudson KM, et al. FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy. Clin Cancer Res. 2025;31(19):4004\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0880.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"3762_CR82","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO-25-00765","volume":"43","author":"T Medina","year":"2025","unstructured":"Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, et al. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. JCO. 2025;43(33):3565\u201372. https:\/\/doi.org\/10.1200\/JCO-25-00765.","journal-title":"JCO"},{"issue":"23","key":"3762_CR83","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387(23):2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med"},{"issue":"8","key":"3762_CR84","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.annonc.2025.04.001","volume":"36","author":"S Mart\u00edn-Lluesma","year":"2025","unstructured":"Mart\u00edn-Lluesma S, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, et al. Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals oncology: official J Eur Soc Med Oncol. 2025;36(8):909\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.001.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"1","key":"3762_CR85","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-017-0279-5","volume":"5","author":"D Davar","year":"2017","unstructured":"Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, et al. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017;5(1):74. https:\/\/doi.org\/10.1186\/s40425-017-0279-5.","journal-title":"J Immunother Cancer"},{"key":"3762_CR86","doi-asserted-by":"publisher","unstructured":"Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11(3):e006398. https:\/\/doi.org\/10.1136\/jitc-2022-006398.","DOI":"10.1136\/jitc-2022-006398"},{"issue":"6522","key":"3762_CR87","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna S, Lowery FJ, Copeland AR, Bahadiroglu E, Mukherjee R, Jia L, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370(6522):1328\u201334. https:\/\/doi.org\/10.1126\/science.abb9847.","journal-title":"Science"},{"issue":"2","key":"3762_CR88","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1046-2023(03)00125-7","volume":"31","author":"JDM Campbell","year":"2003","unstructured":"Campbell JDM. Detection and enrichment of antigen-specific CD4\u2009+\u2009and CD8\u2009+\u2009T cells based on cytokine secretion. Methods. 2003;31(2):150\u20139. https:\/\/doi.org\/10.1016\/s1046-2023(03)00125-7.","journal-title":"Methods"},{"issue":"5","key":"3762_CR89","doi-asserted-by":"publisher","first-page":"e1002723","DOI":"10.1080\/2162402X.2014.1002723","volume":"4","author":"S Kayser","year":"2015","unstructured":"Kayser S, Bo\u03b2 C, Feucht J, Witte K-E, Scheu A, B\u00fclow H-J, et al. Rapid generation of NY-ESO-1-specific CD4\u2009+\u2009THELPER1 cells for adoptive T-cell therapy. OncoImmunology. 2015;4(5):e1002723. https:\/\/doi.org\/10.1080\/2162402X.2014.1002723.","journal-title":"OncoImmunology"},{"key":"3762_CR90","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3389\/fimmu.2020.01215","volume":"11","author":"V Bianchi","year":"2020","unstructured":"Bianchi V, Harari A, Coukos G. Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal. Front Immunol. 2020;11:1215. https:\/\/doi.org\/10.3389\/fimmu.2020.01215.","journal-title":"Front Immunol"},{"key":"3762_CR91","doi-asserted-by":"publisher","first-page":"1483254","DOI":"10.3389\/fimmu.2024.1483254","volume":"15","author":"C V\u00f6lzke","year":"2024","unstructured":"V\u00f6lzke C, Ehrhardt L, Fischer L, Maul P, Wenzel C, Riabinska A, et al. Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system. Front Immunol. 2024;15:1483254. https:\/\/doi.org\/10.3389\/fimmu.2024.1483254.","journal-title":"Front Immunol"},{"issue":"1","key":"3762_CR92","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? OncoImmunology. 2017;7(1):e1364828. https:\/\/doi.org\/10.1080\/2162402X.2017.1364828.","journal-title":"OncoImmunology"},{"issue":"5","key":"3762_CR93","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8\u207a tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246\u201359. https:\/\/doi.org\/10.1172\/JCI73639.","journal-title":"J Clin Invest"},{"issue":"1","key":"3762_CR94","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. https:\/\/doi.org\/10.1038\/s41467-018-05072-0.","journal-title":"Nat Commun"},{"issue":"1","key":"3762_CR95","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","volume":"56","author":"A Chow","year":"2023","unstructured":"Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8\u2009+\u2009T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2023;56(1):93\u2013e1066. https:\/\/doi.org\/10.1016\/j.immuni.2022.12.001.","journal-title":"Immunity"},{"issue":"1","key":"3762_CR96","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imm.12499","volume":"146","author":"G Dolton","year":"2015","unstructured":"Dolton G, Tungatt K, Lloyd A, Bianchi V, Theaker SM, Trimby A, et al. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology. 2015;146(1):11\u201322. https:\/\/doi.org\/10.1111\/imm.12499.","journal-title":"Immunology"},{"issue":"2","key":"3762_CR97","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4049\/jimmunol.1301770","volume":"192","author":"MM van Buuren","year":"2014","unstructured":"van Buuren MM, Dijkgraaf FE, Linnemann C, Toebes M, Chang CXL, Mok JY, et al. HLA micropolymorphisms strongly affect peptide-MHC multimer-based monitoring of antigen-specific CD8\u2009+\u2009T cell responses. J Immunol. 2014;192(2):641\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1301770.","journal-title":"J Immunol"},{"issue":"24","key":"3762_CR98","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","volume":"16","author":"ME Dudley","year":"2010","unstructured":"Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al. CD8\u2009+\u2009enriched young tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16(24):6122\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1297.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3762_CR99","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","volume":"31","author":"KQ Tran","year":"2008","unstructured":"Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31(8):742\u201351. https:\/\/doi.org\/10.1097\/CJI.0b013e31818403d5.","journal-title":"J Immunother"},{"issue":"7","key":"3762_CR100","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00262-019-02354-4","volume":"68","author":"W Gong","year":"2019","unstructured":"Gong W, Hoffmann J-M, Stock S, Wang L, Liu Y, Schubert M-L, et al. Comparison of IL-2 vs IL-7\/IL-15 for the generation of NY-ESO-1-specific T cells. Cancer Immunol Immunother. 2019;68(7):1195\u2013209. https:\/\/doi.org\/10.1007\/s00262-019-02354-4.","journal-title":"Cancer Immunol Immunother"},{"key":"3762_CR101","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1479-5876-11-37","volume":"11","author":"SJAM Santegoets","year":"2013","unstructured":"Santegoets SJAM, Turksma AW, Suhoski MM, Stam AGM, Albelda SM, Hooijberg E, et al. IL-21 promotes the expansion of CD27\u2009+\u2009CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med. 2013;11:37. https:\/\/doi.org\/10.1186\/1479-5876-11-37.","journal-title":"J Transl Med"},{"issue":"4","key":"3762_CR102","doi-asserted-by":"publisher","first-page":"e60031","DOI":"10.1371\/journal.pone.0060031","volume":"8","author":"JA Chacon","year":"2013","unstructured":"Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, et al. Co-stimulation through 4-1BB\/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS ONE. 2013;8(4):e60031. https:\/\/doi.org\/10.1371\/journal.pone.0060031.","journal-title":"PLoS ONE"},{"key":"3762_CR103","doi-asserted-by":"crossref","unstructured":"Thomas SS, Gogas H, Hong YK, In GK, de Doger B, Furness AJ et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A. JCO. 2024;42(16_suppl):9505.","DOI":"10.1200\/JCO.2024.42.16_suppl.9505"},{"issue":"12","key":"3762_CR104","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, et al. Cish actively silences TCR signaling in CD8\u2009+\u2009T cells to maintain tumor tolerance. J Exp Med. 2015;212(12):2095\u2013113. https:\/\/doi.org\/10.1084\/jem.20150304.","journal-title":"J Exp Med"},{"key":"3762_CR105","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","volume":"28","author":"J Lv","year":"2023","unstructured":"Lv J, Le Qin, Zhao R, Di Wu, Wu Z, Zheng D, et al. Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels. Mol Ther Oncolytics. 2023;28:46\u201358. https:\/\/doi.org\/10.1016\/j.omto.2022.12.003.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"3762_CR106","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","volume":"26","author":"E Lou","year":"2025","unstructured":"Lou E, Choudhry MS, Starr TK, Folsom TD, Bell J, Rathmann B, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26(5):559\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(25)00083-X.","journal-title":"Lancet Oncol"},{"key":"3762_CR107","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","volume":"24","author":"CA Chamberlain","year":"2022","unstructured":"Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met \u00d6. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther Oncolytics. 2022;24:417\u201328. https:\/\/doi.org\/10.1016\/j.omto.2022.01.004.","journal-title":"Mol Ther Oncolytics"},{"key":"3762_CR108","doi-asserted-by":"publisher","unstructured":"Fix SM, Forget M-A, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M et al. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-\u03b2 signaling. J Immunother Cancer 2022Jul;10(7):e003750. https:\/\/doi.org\/10.1136\/jitc-2021-003750.","DOI":"10.1136\/jitc-2021-003750"},{"key":"3762_CR109","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1200\/JCO.2025.43.16_suppl.9519","volume":"43","author":"RN Amaria","year":"2025","unstructured":"Amaria RN, Diab A, Tawbi HA, Glitza IC, McQuade JL, Davies MA, et al. OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)\u2013resistant advanced melanoma. JCO. 2025;43:9519. (16_suppl).","journal-title":"JCO"},{"issue":"15suppl","key":"3762_CR110","doi-asserted-by":"publisher","first-page":"TPS9594","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS9594","volume":"34","author":"RN Amaria","year":"2016","unstructured":"Amaria RN, Haymaker CL, Bernatchez C, Forget M-A, Patel V, Hwu W-J, et al. A phase I\/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). JCO. 2016;34(15suppl):TPS9594\u20139594.","journal-title":"JCO"},{"issue":"8","key":"3762_CR111","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1016\/j.ymthe.2025.04.031","volume":"33","author":"RA Burga","year":"2025","unstructured":"Burga RA, Aksoy BA, Ao Z, Tchaicha JH, Sethi DK, Villasmil Ocando A, et al. IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Mol Ther. 2025;33(8):3605\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.031.","journal-title":"Mol Ther"},{"issue":"6382","key":"3762_CR112","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711.","journal-title":"Science"},{"key":"3762_CR113","doi-asserted-by":"publisher","unstructured":"Piscopo NJ, Mueller KP, Das A, Hematti P, Murphy WL, Palecek SP et al. Bioengineering Solutions for Manufacturing Challenges in CAR T Cells. Biotechnol J. 2018;13(2):10.1002\/biot.201700095. https:\/\/doi.org\/10.1002\/biot.201700095.","DOI":"10.1002\/biot.201700095"},{"key":"3762_CR114","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101. https:\/\/doi.org\/10.1016\/j.omtm.2016.12.006.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3762_CR115","doi-asserted-by":"publisher","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","volume":"13","author":"N Watanabe","year":"2022","unstructured":"Watanabe N, Mo F, McKenna MK. Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol. 2022;13:876339. https:\/\/doi.org\/10.3389\/fimmu.2022.876339.","journal-title":"Front Immunol"},{"key":"3762_CR116","doi-asserted-by":"publisher","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","volume":"13","author":"CRF Silveira","year":"2022","unstructured":"Silveira CRF, Corveloni AC, Caruso SR, Mac\u00eado NA, Brussolo NM, Haddad F, et al. Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol. 2022;13:947648. https:\/\/doi.org\/10.3389\/fimmu.2022.947648.","journal-title":"Front Immunol"},{"issue":"26","key":"3762_CR117","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377(26):2545\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1708566.","journal-title":"N Engl J Med"},{"issue":"7","key":"3762_CR118","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"issue":"4","key":"3762_CR119","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"3762_CR120","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2024;390(7):584\u20136. https:\/\/doi.org\/10.1056\/NEJMp2400209.","journal-title":"N Engl J Med"},{"key":"3762_CR121","doi-asserted-by":"publisher","unstructured":"Soltantoyeh T, Akbari B, Karimi A, Mahmoodi Chalbatani G, Ghahri-Saremi N, Hadjati J et al. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells. 2021;10(6):1450. https:\/\/doi.org\/10.3390\/cells10061450","DOI":"10.3390\/cells10061450"},{"issue":"5","key":"3762_CR122","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clin Cancer Res. 2021;27(5):1227\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2584.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3762_CR123","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","volume":"31","author":"S Seaman","year":"2017","unstructured":"Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. Eradication of Tumors through Simultaneous Ablation of CD276\/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell. 2017;31(4):501\u2013e5158. https:\/\/doi.org\/10.1016\/j.ccell.2017.03.005.","journal-title":"Cancer Cell"},{"issue":"35","key":"3762_CR124","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, et al. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed\/Refractory Solid Tumors. JCO. 2024;42(35):4163\u201372. https:\/\/doi.org\/10.1200\/JCO.23.02229.","journal-title":"JCO"},{"key":"3762_CR125","doi-asserted-by":"publisher","unstructured":"Maher J, Davies DM. CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens. Biology (Basel). 2023;12(2):287. https:\/\/doi.org\/10.3390\/biology12020287.","DOI":"10.3390\/biology12020287"},{"key":"3762_CR126","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/ITT.S507522","volume":"14","author":"Y Guo","year":"2025","unstructured":"Guo Y, Wang X, Zhang C, Chen W, Fu Y, Yu Y, et al. Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications. Immunotargets Ther. 2025;14:291\u2013320. https:\/\/doi.org\/10.2147\/ITT.S507522.","journal-title":"Immunotargets Ther"},{"issue":"722","key":"3762_CR127","doi-asserted-by":"publisher","first-page":"eadf6732","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku S-Y, Garcia MM, et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023;15(722):eadf6732. https:\/\/doi.org\/10.1126\/scitranslmed.adf6732.","journal-title":"Sci Transl Med"},{"key":"3762_CR128","doi-asserted-by":"publisher","first-page":"216074","DOI":"10.1016\/j.canlet.2023.216074","volume":"556","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Zhou J, Li L, Liao S, He J, Zhou S, et al. Pericytes in the tumor microenvironment. Cancer Lett. 2023;556:216074. https:\/\/doi.org\/10.1016\/j.canlet.2023.216074.","journal-title":"Cancer Lett"},{"issue":"1","key":"3762_CR129","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12967-022-03679-y","volume":"20","author":"L Boudin","year":"2022","unstructured":"Boudin L, de Nonneville A, Finetti P, Mescam L, Le Cesne A, Italiano A, et al. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response. J Transl Med. 2022;20(1):464.","journal-title":"J Transl Med"},{"key":"3762_CR130","doi-asserted-by":"publisher","unstructured":"Chen X, Habib S, Alexandru M, Chauhan J, Evan T, Troka JM, et al. Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma. Cancers (Basel). 2024;16(19):3260. https:\/\/doi.org\/10.3390\/cancers16193260.","DOI":"10.3390\/cancers16193260"},{"key":"3762_CR131","doi-asserted-by":"publisher","unstructured":"Wiesinger M, M\u00e4rz J, Kummer M, Schuler G, D\u00f6rrie J, Schuler-Thurner B, et al. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance. Cancers (Basel). 2019;11(8):1198. https:\/\/doi.org\/10.3390\/cancers11081198.","DOI":"10.3390\/cancers11081198"},{"issue":"1","key":"3762_CR132","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-023-02884-x","volume":"42","author":"L Giraudo","year":"2023","unstructured":"Giraudo L, Cattaneo G, Gammaitoni L, Iaia I, Donini C, Massa A, et al. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma. J Exp Clin Cancer Res. 2023;42(1):310. https:\/\/doi.org\/10.1186\/s13046-023-02884-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"3762_CR133","doi-asserted-by":"publisher","first-page":"878365","DOI":"10.3389\/fimmu.2022.878365","volume":"13","author":"KM Knudson","year":"2022","unstructured":"Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK. Recent Advances in IL-13R\u03b12-Directed Cancer Immunotherapy. Front Immunol. 2022;13:878365. https:\/\/doi.org\/10.3389\/fimmu.2022.878365.","journal-title":"Front Immunol"},{"issue":"4","key":"3762_CR134","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u201312. https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","journal-title":"Nat Med"},{"issue":"1","key":"3762_CR135","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","volume":"15","author":"S Jilani","year":"2024","unstructured":"Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, et al. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun. 2024;15(1):1244. https:\/\/doi.org\/10.1038\/s41467-024-45221-2.","journal-title":"Nat Commun"},{"issue":"4","key":"3762_CR136","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2015.03.004","volume":"27","author":"EF Zhu","year":"2015","unstructured":"Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell. 2015;27(4):489\u2013501. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.004","journal-title":"Cancer Cell"},{"issue":"21","key":"3762_CR137","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1158\/1078-0432.CCR-16-1241","volume":"22","author":"DN Khalil","year":"2016","unstructured":"Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SRP, et al. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016;22(21):5204\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1241.","journal-title":"Clin Cancer Res"},{"key":"3762_CR138","doi-asserted-by":"publisher","first-page":"1249929","DOI":"10.3389\/fphar.2023.1249929","volume":"14","author":"P Machy","year":"2023","unstructured":"Machy P, Mortier E, Birkl\u00e9 S. Biology of GD2 ganglioside: implications for cancer immunotherapy. Front Pharmacol. 2023;14:1249929. https:\/\/doi.org\/10.3389\/fphar.2023.1249929.","journal-title":"Front Pharmacol"},{"issue":"14","key":"3762_CR139","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, de Angelis B, Caruana I, Del Baldo G, de Ioris MA, Serra A, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2210859.","journal-title":"N Engl J Med"},{"issue":"11","key":"3762_CR140","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","volume":"31","author":"F Locatelli","year":"2025","unstructured":"Locatelli F, Pagliara D, de Ioris MA, Becilli M, Del Baldo G, Serra A, et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial. Nat Med. 2025;31(11):3689\u201399. https:\/\/doi.org\/10.1038\/s41591-025-03874-6.","journal-title":"Nat Med"},{"issue":"8046","key":"3762_CR141","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025;637(8046):708\u201315. https:\/\/doi.org\/10.1038\/s41586-024-08171-9.","journal-title":"Nature"},{"key":"3762_CR142","doi-asserted-by":"publisher","unstructured":"Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A et al. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. J Immunother Cancer. 2024;12(5):e008659. https:\/\/doi.org\/10.1136\/jitc-2023-008659.","DOI":"10.1136\/jitc-2023-008659"},{"issue":"3","key":"3762_CR143","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/1744666X.2021.1880895","volume":"17","author":"A Razavi","year":"2021","unstructured":"Razavi A, Keshavarz-Fathi M, Pawelek J, Rezaei N. Chimeric antigen receptor T-cell therapy for melanoma. Expert Rev Clin Immunol. 2021;17(3):209\u201323. https:\/\/doi.org\/10.1080\/1744666X.2021.1880895.","journal-title":"Expert Rev Clin Immunol"},{"key":"3762_CR144","doi-asserted-by":"publisher","first-page":"1643941","DOI":"10.3389\/fimmu.2025.1643941","volume":"16","author":"DD Yang","year":"2025","unstructured":"Yang DD, Macmorland W, Arnold JN. Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment. Front Immunol. 2025;16:1643941. https:\/\/doi.org\/10.3389\/fimmu.2025.1643941.","journal-title":"Front Immunol"},{"issue":"11","key":"3762_CR145","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? Mol Ther. 2020;28(11):2320\u201339. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.015.","journal-title":"Mol Ther"},{"key":"3762_CR146","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2021.09.003","volume":"74","author":"S Simon","year":"2022","unstructured":"Simon S, Bugos G, Salter AI, Riddell SR. Synthetic receptors for logic gated T cell recognition and function. Curr Opin Immunol. 2022;74:9\u201317. https:\/\/doi.org\/10.1016\/j.coi.2021.09.003.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"3762_CR147","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41423-024-01153-x","volume":"21","author":"B Zhu","year":"2024","unstructured":"Zhu B, Yin H, Di Zhang, Zhang M, Chao X, Scimeca L, et al. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy. Cell Mol Immunol. 2024;21(5):436\u201347. https:\/\/doi.org\/10.1038\/s41423-024-01153-x.","journal-title":"Cell Mol Immunol"},{"key":"3762_CR148","doi-asserted-by":"publisher","unstructured":"Stucchi S, Borea R, Garcia-Recio S, Zingarelli M, R\u00e4dler PD, Camerini E et al. B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer. J Immunother Cancer. 2025;13(5):e011533. https:\/\/doi.org\/10.1136\/jitc-2025-011533.","DOI":"10.1136\/jitc-2025-011533"},{"issue":"6520","key":"3762_CR149","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1126\/science.abc6270","volume":"370","author":"JZ Williams","year":"2020","unstructured":"Williams JZ, Allen GM, Shah D, Sterin IS, Kim KH, Garcia VP, et al. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science. 2020;370(6520):1099\u2013104. https:\/\/doi.org\/10.1126\/science.abc6270.","journal-title":"Science"},{"key":"3762_CR150","doi-asserted-by":"publisher","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13(591):eabd8836. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836.","DOI":"10.1126\/scitranslmed.abd8836"},{"key":"3762_CR151","doi-asserted-by":"publisher","first-page":"1638186","DOI":"10.3389\/fimmu.2025.1638186","volume":"16","author":"T Andreou","year":"2025","unstructured":"Andreou T, Neophytou C, Kalli M, Mpekris F, Stylianopoulos T. Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling. Front Immunol. 2025;16:1638186. https:\/\/doi.org\/10.3389\/fimmu.2025.1638186.","journal-title":"Front Immunol"},{"key":"3762_CR152","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377. https:\/\/doi.org\/10.1016\/j.omto.2022.03.009.","journal-title":"Mol Ther Oncolytics"},{"key":"3762_CR153","doi-asserted-by":"publisher","unstructured":"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ, et al. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng. 2025;10(4):613\u201329. https:\/\/doi.org\/10.1038\/s41551-025-01509-2.","DOI":"10.1038\/s41551-025-01509-2"},{"key":"3762_CR154","doi-asserted-by":"publisher","unstructured":"Kessel C, Rossig C, Abken H. Weal and woe of interleukin-18 in the T cell therapy of cancer. J Immunother Cancer. 2025;13(1):e010545. https:\/\/doi.org\/10.1136\/jitc-2024-010545.","DOI":"10.1136\/jitc-2024-010545"},{"key":"3762_CR155","doi-asserted-by":"publisher","unstructured":"Rafii S, Mukherji D, Komaranchath AS, Khalil C, Iqbal F, Abdelwahab SI, et al. Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. Cancers (Basel). 2025;17(17):2898. https:\/\/doi.org\/10.3390\/cancers17172898.","DOI":"10.3390\/cancers17172898"},{"key":"3762_CR156","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Abken H. TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation. Adv Cell Gene Ther 2020;3(3).","DOI":"10.1002\/acg2.84"},{"key":"3762_CR157","doi-asserted-by":"crossref","unstructured":"Svoboda J, Landsburg DJ, Nasta SD, Barta SK, Chong EA, Lariviere MJ et al. Safety and efficacy of armored huCART19-IL18 in patients with relapsed\/refractory lymphomas that progressed after anti-CD19 CAR T cells. JCO 2024;42(16_suppl):7004.","DOI":"10.1200\/JCO.2024.42.16_suppl.7004"},{"issue":"1","key":"3762_CR158","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12(1):3236. https:\/\/doi.org\/10.1038\/s41467-021-23331-5.","journal-title":"Nat Commun"},{"issue":"3","key":"3762_CR159","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127(3):929\u201341. https:\/\/doi.org\/10.1172\/JCI89455.","journal-title":"J Clin Invest"},{"issue":"1","key":"3762_CR160","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","volume":"39","author":"E Masoumi","year":"2020","unstructured":"Masoumi E, Jafarzadeh L, Mirzaei HR, Alishah K, Fallah-Mehrjardi K, Rostamian H, et al. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells. J Exp Clin Cancer Res. 2020;39(1):49. https:\/\/doi.org\/10.1186\/s13046-020-01546-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3762_CR161","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-022-03290-6","volume":"72","author":"K Li","year":"2023","unstructured":"Li K, Xu J, Wang J, Lu C, Dai Y, Dai Q, et al. Dominant-negative transforming growth factor-\u03b2 receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer. Cancer Immunol Immunother. 2023;72(4):917\u201328. https:\/\/doi.org\/10.1007\/s00262-022-03290-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3762_CR162","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/imm.13888","volume":"174","author":"S Zhu","year":"2025","unstructured":"Zhu S, Hu J, Lin J, Wang C, Wang E. Co-Expression of Dominant-Negative TGF-\u03b2 Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1\/DAP12-BB-Based CAR-T Cells in Solid Tumours. Immunology. 2025;174(3):310\u201321. https:\/\/doi.org\/10.1111\/imm.13888.","journal-title":"Immunology"},{"key":"3762_CR163","doi-asserted-by":"publisher","unstructured":"Whilding LM, Halim L, Draper B, Parente-Pereira AC, Zabinski T, Davies DM, et al. CAR T-Cells Targeting the Integrin \u03b1v\u03b26 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. Cancers (Basel). 2019;11(5):674. https:\/\/doi.org\/10.3390\/cancers11050674.","DOI":"10.3390\/cancers11050674"},{"issue":"14","key":"3762_CR164","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0351.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3762_CR165","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Li P, Zeng X, Guo J, Zhang C, Fan Z, et al. CAR-T therapy dilemma and innovative design strategies for next generation. Cell Death Dis. 2025;16(1):211. https:\/\/doi.org\/10.1038\/s41419-025-07454-x.","journal-title":"Cell Death Dis"},{"issue":"5","key":"3762_CR166","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712\u201324. https:\/\/doi.org\/10.1002\/eji.201948457.","journal-title":"Eur J Immunol"},{"issue":"4","key":"3762_CR167","doi-asserted-by":"publisher","first-page":"eads3403","DOI":"10.1126\/sciadv.ads3403","volume":"11","author":"KC Vogt","year":"2025","unstructured":"Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, et al. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci Adv. 2025;11(4):eads3403. https:\/\/doi.org\/10.1126\/sciadv.ads3403.","journal-title":"Sci Adv"},{"key":"3762_CR168","doi-asserted-by":"publisher","first-page":"39833","DOI":"10.1038\/srep39833","volume":"7","author":"A Juillerat","year":"2017","unstructured":"Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, Duclert A, et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep. 2017;7:39833. https:\/\/doi.org\/10.1038\/srep39833.","journal-title":"Sci Rep"},{"issue":"4","key":"3762_CR169","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.xcrm.2021.100227","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2(4):100227. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100227.","journal-title":"Cell Rep Med"},{"issue":"1","key":"3762_CR170","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, et al. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov. 2023;13(1):114\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0750.","journal-title":"Cancer Discov"},{"key":"3762_CR171","doi-asserted-by":"publisher","first-page":"755639","DOI":"10.3389\/fimmu.2021.755639","volume":"12","author":"M Guercio","year":"2021","unstructured":"Guercio M, Manni S, Boffa I, Caruso S, Di Cecca S, Sinibaldi M, et al. Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies. Front Immunol. 2021;12:755639. https:\/\/doi.org\/10.3389\/fimmu.2021.755639.","journal-title":"Front Immunol"},{"issue":"11","key":"3762_CR172","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247\u201354. https:\/\/doi.org\/10.1182\/blood-2004-11-4564.","journal-title":"Blood"},{"key":"3762_CR173","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235. https:\/\/doi.org\/10.3389\/fphar.2014.00235.","journal-title":"Front Pharmacol"},{"issue":"8","key":"3762_CR174","doi-asserted-by":"publisher","first-page":"eadj6251","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu L, Xie M, Yang B, Zhao W-B, Cao J. Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control. Sci Adv. 2024;10(8):eadj6251. https:\/\/doi.org\/10.1126\/sciadv.adj6251.","journal-title":"Sci Adv"},{"issue":"8","key":"3762_CR175","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jcyt.2024.03.484","volume":"26","author":"GC Russell","year":"2024","unstructured":"Russell GC, Hamzaoui Y, Rho D, Sutrave G, Choi JS, Missan DS, et al. Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers. Cytotherapy. 2024;26(8):842\u201357. https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.484.","journal-title":"Cytotherapy"},{"issue":"15","key":"3762_CR176","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1158\/1078-0432.CCR-24-0071","volume":"30","author":"M Ventin","year":"2024","unstructured":"Ventin M, Cattaneo G, Arya S, Jia J, Gelmi MC, Sun Y, et al. Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. Clin Cancer Res. 2024;30(15):3243\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0071.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3762_CR177","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-021-00455-x","volume":"4","author":"C Jiao","year":"2021","unstructured":"Jiao C, Zvonkov E, Lai X, Zhang R, Liu Y, Qin Y, et al. SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed\/refractory B cell lymphomas. Blood Cancer J. 2021;4(3):59. https:\/\/doi.org\/10.1038\/s41408-021-00455-x.","journal-title":"Blood Cancer J"},{"issue":"1","key":"3762_CR178","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ped4.12181","volume":"4","author":"X Xu","year":"2020","unstructured":"Xu X, Zhao W, Yue Z, Qin M, Jin M, Chang L-J, et al. 4SCAR-GD2-modified T-cell therapy in neuroblastoma with MYCN amplification: A case report with over 4-year follow-up data. Pediatr Investig. 2020;4(1):55\u20138. https:\/\/doi.org\/10.1002\/ped4.12181.","journal-title":"Pediatr Investig"},{"issue":"1","key":"3762_CR179","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22(1):3. https:\/\/doi.org\/10.1186\/s12943-022-01711-9.","journal-title":"Mol Cancer"},{"key":"3762_CR180","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022;13:835762. https:\/\/doi.org\/10.3389\/fimmu.2022.835762.","journal-title":"Front Immunol"},{"issue":"1","key":"3762_CR181","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12967-025-06524-0","volume":"23","author":"L Dan","year":"2025","unstructured":"Dan L, Kang-Zheng L. Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations. J Transl Med. 2025;23(1):501. https:\/\/doi.org\/10.1186\/s12967-025-06524-0.","journal-title":"J Transl Med"},{"issue":"7","key":"3762_CR182","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023;9(7):eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700.","journal-title":"Sci Adv"},{"issue":"13","key":"3762_CR183","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","volume":"3","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Faitg TH, Lowther DE, Badros AZ, Chagin K, Dengel K, et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Adv. 2019;3(13):2022\u201334. https:\/\/doi.org\/10.1182\/bloodadvances.2019000194.","journal-title":"Blood Adv"},{"issue":"1","key":"3762_CR184","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J, Celichowski P, Mih\u00e1lyov\u00e1 J, Charv\u00e1tov\u00e1 S, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):213. https:\/\/doi.org\/10.1038\/s41408-024-01193-6.","journal-title":"Blood Cancer J"},{"key":"3762_CR185","doi-asserted-by":"publisher","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221(2):e20230903. https:\/\/doi.org\/10.1084\/jem.20230903","DOI":"10.1084\/jem.20230903"},{"issue":"7","key":"3762_CR186","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. JCO. 2011;29(7):917\u201324. https:\/\/doi.org\/10.1200\/JCO.2010.32.2537.","journal-title":"JCO"},{"key":"3762_CR187","doi-asserted-by":"crossref","unstructured":"Rohaan MW, Gomez-Eerland R, van den Berg JH, Geukes Foppen MH, van Zon M, Raud B et al. MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I\/IIa clinical trial. Immunooncol Technol. 2022;15:100089. Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/35865122\/.","DOI":"10.1016\/j.iotech.2022.100089"},{"issue":"11","key":"3762_CR188","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","volume":"42","author":"C Lezcano","year":"2018","unstructured":"Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol. 2018;42(11):1456\u201365. https:\/\/doi.org\/10.1097\/PAS.0000000000001134.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"3762_CR189","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02\u2009+\u2009patients: a phase 1 trial. Nat Med. 2025;31(7):2365\u201374. https:\/\/doi.org\/10.1038\/s41591-025-03650-6.","journal-title":"Nat Med"},{"issue":"16suppl","key":"3762_CR190","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2025.43.16_suppl.2508","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Alsdorf W, Araujo DM, Busse A, Chatterjee M, Hernandez-Aya LF, et al. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma. JCO. 2025;43(16suppl):2508.","journal-title":"JCO"},{"key":"3762_CR191","doi-asserted-by":"crossref","unstructured":"Luke JJ, Betof Warner A, Chmielowski B, Diab A, Gebhardt C, Hernandez-Aya LF et al. SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator\u2019s choice in patients with previously treated advanced cutaneous melanoma. JCO 2025;43(16_suppl).","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2673"},{"issue":"6","key":"3762_CR192","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863\u201371. https:\/\/doi.org\/10.1182\/blood-2013-03-490565.","journal-title":"Blood"},{"key":"3762_CR193","doi-asserted-by":"publisher","first-page":"18851","DOI":"10.1038\/srep18851","volume":"6","author":"MCC Raman","year":"2016","unstructured":"Raman MCC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, et al. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Sci Rep. 2016;6:18851. https:\/\/doi.org\/10.1038\/srep18851.","journal-title":"Sci Rep"},{"issue":"1","key":"3762_CR194","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","volume":"22","author":"EA Golikova","year":"2024","unstructured":"Golikova EA, Alshevskaya AA, Alrhmoun S, Sivitskaya NA, Sennikov SV. TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges. J Transl Med. 2024;22(1):897. https:\/\/doi.org\/10.1186\/s12967-024-05703-9.","journal-title":"J Transl Med"},{"key":"3762_CR195","doi-asserted-by":"crossref","unstructured":"Sun Q, Zhang X, Wang L, Gao X, Xiong Y, Liu L et al. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death Dis. 2019;10(7):475. Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/31209257\/.","DOI":"10.1038\/s41419-019-1717-8"},{"key":"3762_CR196","doi-asserted-by":"publisher","first-page":"850358","DOI":"10.3389\/fimmu.2022.850358","volume":"13","author":"F Wei","year":"2022","unstructured":"Wei F, Cheng X-X, Xue JZ, Xue S-A. Emerging Strategies in TCR-Engineered T Cells. Front Immunol. 2022;13:850358. https:\/\/doi.org\/10.3389\/fimmu.2022.850358.","journal-title":"Front Immunol"},{"issue":"7","key":"3762_CR197","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","volume":"22","author":"GI Ellis","year":"2021","unstructured":"Ellis GI, Sheppard NC, Riley JL. Genetic engineering of T cells for immunotherapy. Nat Rev Genet. 2021;22(7):427\u201347. https:\/\/doi.org\/10.1038\/s41576-021-00329-9.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"3762_CR198","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2708.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3762_CR199","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/jimmun\/vkaf036","volume":"214","author":"S Ma","year":"2025","unstructured":"Ma S, Yu J, Caligiuri MA. Natural killer cell-based immunotherapy for cancer. J Immunol. 2025;214(7):1444\u201356. https:\/\/doi.org\/10.1093\/jimmun\/vkaf036.","journal-title":"J Immunol"},{"key":"3762_CR200","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fimmu.2015.00649","volume":"6","author":"R Tarazona","year":"2015","unstructured":"Tarazona R, Duran E, Solana R. Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol. 2015;6:649. https:\/\/doi.org\/10.3389\/fimmu.2015.00649.","journal-title":"Front Immunol"},{"issue":"6","key":"3762_CR201","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105(6):1319\u201329. https:\/\/doi.org\/10.1002\/JLB.MR0718-269R.","journal-title":"J Leukoc Biol"},{"issue":"9","key":"3762_CR202","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00262-009-0682-y","volume":"58","author":"JG Casado","year":"2009","unstructured":"Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother. 2009;58(9):1517\u201326. https:\/\/doi.org\/10.1007\/s00262-009-0682-y.","journal-title":"Cancer Immunol Immunother"},{"key":"3762_CR203","doi-asserted-by":"crossref","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther. 2024;9(1):302. Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/39511139\/.","DOI":"10.1038\/s41392-024-02005-w"},{"issue":"8","key":"3762_CR204","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","volume":"25","author":"H Netskar","year":"2024","unstructured":"Netskar H, Pfefferle A, Goodridge JP, Sohlberg E, Dufva O, Teichmann SA, et al. Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nat Immunol. 2024;25(8):1445\u201359. https:\/\/doi.org\/10.1038\/s41590-024-01884-z.","journal-title":"Nat Immunol"},{"issue":"2","key":"3762_CR205","doi-asserted-by":"publisher","first-page":"e1537581","DOI":"10.1080\/2162402X.2018.1537581","volume":"8","author":"H Lee","year":"2019","unstructured":"Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, et al. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. OncoImmunology. 2019;8(2):e1537581. https:\/\/doi.org\/10.1080\/2162402X.2018.1537581.","journal-title":"OncoImmunology"},{"key":"3762_CR206","doi-asserted-by":"publisher","unstructured":"Lee H, Da Silva IP, Palendira U, Scolyer RA, Long GV, Wilmott JS. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers (Basel). 2021;13(6):1363. https:\/\/doi.org\/10.3390\/cancers13061363.","DOI":"10.3390\/cancers13061363"},{"key":"3762_CR207","doi-asserted-by":"crossref","unstructured":"Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 2012; 72(6):1407\u201315. Available from: URL: https:\/\/pubmed.ncbi.nlm.nih.gov\/22258454\/.","DOI":"10.1158\/0008-5472.CAN-11-2544"},{"key":"3762_CR208","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3389\/fimmu.2015.00482","volume":"6","author":"M Hasmim","year":"2015","unstructured":"Hasmim M, Messai Y, Ziani L, Thiery J, Bouhris J-H, Noman MZ, et al. Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. Front Immunol. 2015;6:482. https:\/\/doi.org\/10.3389\/fimmu.2015.00482.","journal-title":"Front Immunol"},{"issue":"1","key":"3762_CR209","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12967-024-05033-w","volume":"22","author":"L Miao","year":"2024","unstructured":"Miao L, Lu C, Zhang B, Li H, Zhao X, Chen H, et al. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy. J Transl Med. 2024;22(1):229. https:\/\/doi.org\/10.1186\/s12967-024-05033-w.","journal-title":"J Transl Med"},{"issue":"5","key":"3762_CR210","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016;24(5):657\u201371. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.011.","journal-title":"Cell Metab"},{"key":"3762_CR211","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","volume":"10","author":"A Bruno","year":"2019","unstructured":"Bruno A, Mortara L, Baci D, Noonan DM, Albini A. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. Front Immunol. 2019;10:771. https:\/\/doi.org\/10.3389\/fimmu.2019.00771.","journal-title":"Front Immunol"},{"issue":"24","key":"3762_CR212","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.1158\/0008-5472.CAN-14-1339","volume":"74","author":"L Ferrari de Andrade","year":"2014","unstructured":"Ferrari de Andrade L, Ngiow SF, Stannard K, Rusakiewicz S, Kalimutho M, Khanna KK, et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 2014;74(24):7298\u2013308. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1339.","journal-title":"Cancer Res"},{"issue":"10","key":"3762_CR213","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault M-C, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128(10):4654\u201368. https:\/\/doi.org\/10.1172\/JCI99317.","journal-title":"J Clin Invest"},{"issue":"1","key":"3762_CR214","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12935-023-03134-y","volume":"23","author":"A Rahimi","year":"2023","unstructured":"Rahimi A, Malakoutikhah Z, Rahimmanesh I, Ferns GA, Nedaeinia R, Ishaghi SMM, et al. The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies. Cancer Cell Int. 2023;23(1):312. https:\/\/doi.org\/10.1186\/s12935-023-03134-y.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"3762_CR215","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/cr.2012.128","volume":"22","author":"X Wang","year":"2012","unstructured":"Wang X, Cui Y, Luo G, Wang Q, Hu J, He W, et al. Activated mouse CD4(+)Foxp3(-) T cells facilitate melanoma metastasis via Qa-1-dependent suppression of NK-cell cytotoxicity. Cell Res. 2012;22(12):1696\u2013706. https:\/\/doi.org\/10.1038\/cr.2012.128.","journal-title":"Cell Res"},{"key":"3762_CR216","doi-asserted-by":"publisher","unstructured":"van Vliet AA, Georgoudaki A-M, Raimo M, de Gruijl TD, Spanholtz J. Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma. Cancers (Basel). 2021;13(18):4722. https:\/\/doi.org\/10.3390\/cancers13184722.","DOI":"10.3390\/cancers13184722"},{"issue":"5562","key":"3762_CR217","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097\u2013100. https:\/\/doi.org\/10.1126\/science.1068440.","journal-title":"Science"},{"issue":"8","key":"3762_CR218","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137. https:\/\/doi.org\/10.1182\/blood-2004-07-2974.","journal-title":"Blood"},{"issue":"19","key":"3762_CR219","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/bloodadvances.2018019059","volume":"2","author":"X Zhao","year":"2018","unstructured":"Zhao X, Weinhold S, Brands J, Hejazi M, Degistirici \u00d6, K\u00f6gler G, et al. NK cell development in a human stem cell niche: KIR expression occurs independently of the presence of HLA class I ligands. Blood Adv. 2018;2(19):2452\u201361. https:\/\/doi.org\/10.1182\/bloodadvances.2018019059.","journal-title":"Blood Adv"},{"issue":"4","key":"3762_CR220","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","volume":"65","author":"PSA Becker","year":"2016","unstructured":"Becker PSA, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. 2016;65(4):477\u201384. https:\/\/doi.org\/10.1007\/s00262-016-1792-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"3762_CR221","doi-asserted-by":"publisher","first-page":"e20740","DOI":"10.1371\/journal.pone.0020740","volume":"6","author":"J Spanholtz","year":"2011","unstructured":"Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE. 2011;6(6):e20740. https:\/\/doi.org\/10.1371\/journal.pone.0020740.","journal-title":"PLoS ONE"},{"issue":"7","key":"3762_CR222","doi-asserted-by":"publisher","first-page":"107078","DOI":"10.1016\/j.isci.2023.107078","volume":"26","author":"AA van Vliet","year":"2023","unstructured":"van Vliet AA, Peters E, Vodegel D, Steenmans D, Raimo M, Gibbs S, et al. Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34\u2009+\u2009progenitor cell-derived NK cells. iScience. 2023;26(7):107078. https:\/\/doi.org\/10.1016\/j.isci.2023.107078.","journal-title":"iScience"},{"issue":"24","key":"3762_CR223","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","volume":"120","author":"R Romee","year":"2012","unstructured":"Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012;120(24):4751\u201360. https:\/\/doi.org\/10.1182\/blood-2012-04-419283.","journal-title":"Blood"},{"issue":"357","key":"3762_CR224","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123. https:\/\/doi.org\/10.1126\/scitranslmed.aaf2341.","journal-title":"Sci Transl Med"},{"issue":"17","key":"3762_CR225","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-21-0851","volume":"27","author":"ND Marin","year":"2021","unstructured":"Marin ND, Krasnick BA, Becker-Hapak M, Conant L, Goedegebuure SP, Berrien-Elliott MM, et al. Memory-like Differentiation Enhances NK Cell Responses to Melanoma. Clin Cancer Res. 2021;27(17):4859\u201369. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0851.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3762_CR226","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","volume":"18","author":"RM Shapiro","year":"2025","unstructured":"Shapiro RM, Sheffer M, Booker MA, Tolstorukov MY, Birch GC, Sade-Feldman M, et al. First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer. J Hematol Oncol. 2025;18(1):17. https:\/\/doi.org\/10.1186\/s13045-025-01669-3.","journal-title":"J Hematol Oncol"},{"key":"3762_CR227","doi-asserted-by":"publisher","first-page":"607131","DOI":"10.3389\/fimmu.2020.607131","volume":"11","author":"S Mantesso","year":"2020","unstructured":"Mantesso S, Geerts D, Spanholtz J, Ku\u010derov\u00e1 L. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function. Front Immunol. 2020;11:607131. https:\/\/doi.org\/10.3389\/fimmu.2020.607131.","journal-title":"Front Immunol"},{"key":"3762_CR228","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Front Immunol. 2018;9:283. https:\/\/doi.org\/10.3389\/fimmu.2018.00283.","journal-title":"Front Immunol"},{"key":"3762_CR229","doi-asserted-by":"publisher","first-page":"1384039","DOI":"10.3389\/fimmu.2024.1384039","volume":"15","author":"JC Kong","year":"2024","unstructured":"Kong JC, Sa\u2019ad MA, Vijayan HM, Ravichandran M, Balakrishnan V, Tham SK, et al. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Front Immunol. 2024;15:1384039. https:\/\/doi.org\/10.3389\/fimmu.2024.1384039.","journal-title":"Front Immunol"},{"issue":"1","key":"3762_CR230","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1038\/s41598-020-59082-4","volume":"10","author":"N Mitwasi","year":"2020","unstructured":"Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, et al. UniCAR-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci Rep. 2020;10(1):2141. https:\/\/doi.org\/10.1038\/s41598-020-59082-4.","journal-title":"Sci Rep"},{"key":"3762_CR231","doi-asserted-by":"publisher","unstructured":"Grote S, Ure\u00f1a-Bail\u00e9n G, Chan KC-H, Baden C, Mezger M, Handgretinger R et al. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. Cells. 2021;10(5).https:\/\/doi.org\/10.3390\/cells10051020https:\/\/pubmed.ncbi.nlm.nih.gov\/33925968\/","DOI":"10.3390\/cells10051020"},{"key":"3762_CR232","doi-asserted-by":"publisher","first-page":"1658580","DOI":"10.3389\/fimmu.2025.1658580","volume":"16","author":"X Xu","year":"2025","unstructured":"Xu X, Cao P, Wang M, Wan Y, Sun S, Chen Y, et al. Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK cells. Front Immunol. 2025;16:1658580. https:\/\/doi.org\/10.3389\/fimmu.2025.1658580.","journal-title":"Front Immunol"},{"key":"3762_CR233","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3389\/fimmu.2018.02159","volume":"9","author":"KH Susek","year":"2018","unstructured":"Susek KH, Karvouni M, Alici E, Lundqvist A. The Role of CXC Chemokine Receptors 1\u20134 on Immune Cells in the Tumor Microenvironment. Front Immunol. 2018;9:2159. https:\/\/doi.org\/10.3389\/fimmu.2018.02159.","journal-title":"Front Immunol"},{"issue":"4","key":"3762_CR234","doi-asserted-by":"publisher","first-page":"201061","DOI":"10.1016\/j.omton.2025.201061","volume":"33","author":"S Eguchi","year":"2025","unstructured":"Eguchi S, Luo W, Zhu H, Rosenblum JM, Cooper AR, Cairo MS. Advances in augmenting infiltration of active natural killer cells into pediatric and adult solid tumors. Mol Ther Oncol. 2025;33(4):201061. https:\/\/doi.org\/10.1016\/j.omton.2025.201061.","journal-title":"Mol Ther Oncol"},{"key":"3762_CR235","doi-asserted-by":"publisher","unstructured":"Cho S, Choi SH, Maeng E, Park H, Ryu KS, Park K-S. Boosting tumor homing of endogenous natural killer cells via therapeutic secretomes of chemically primed natural killer cells. J Immunother Cancer. 2025;13(3):e010371. https:\/\/doi.org\/10.1136\/jitc-2024-010371.","DOI":"10.1136\/jitc-2024-010371"},{"issue":"3","key":"3762_CR236","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jcyt.2016.12.005","volume":"19","author":"ES Yvon","year":"2017","unstructured":"Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barese C, et al. Cord blood natural killer cells expressing a dominant negative TGF-\u03b2 receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy. 2017;19(3):408\u201318. https:\/\/doi.org\/10.1016\/j.jcyt.2016.12.005.","journal-title":"Cytotherapy"},{"issue":"9","key":"3762_CR237","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E, Kaufman DS. Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell. 2024;31(9):1327\u2013e13435. https:\/\/doi.org\/10.1016\/j.stem.2024.06.009.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"3762_CR238","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, Ngiow SF, Gao Y, Patch A-M, Barkauskas DS, Messaoudene M, et al. A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Res. 2018;78(4):1003\u201316. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2826.","journal-title":"Cancer Res"},{"issue":"6","key":"3762_CR239","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1910607.","journal-title":"N Engl J Med"},{"issue":"14","key":"3762_CR240","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","volume":"22","author":"DA Vallera","year":"2016","unstructured":"Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33\u2009+\u2009Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016;22(14):3440\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2710.","journal-title":"Clin Cancer Res"},{"key":"3762_CR241","doi-asserted-by":"crossref","unstructured":"Felices M, Warlick E, Juckett M, Weisdorf D, Vallera D, Miller S, et al. 444 GTB-3550 tri-specific killer engager TriKE\u2122 drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients. BMJ Publishing Group Ltd; 2021;A473\u2013473.","DOI":"10.1136\/jitc-2021-SITC2021.444"},{"key":"3762_CR242","doi-asserted-by":"publisher","unstructured":"Hibler W, Merlino G, Yu Y. CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects. Cells. 2023;12(23):2750. https:\/\/doi.org\/10.3390\/cells12232750.","DOI":"10.3390\/cells12232750"},{"issue":"1","key":"3762_CR243","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1186\/s12885-022-10320-0","volume":"22","author":"M Bahmanyar","year":"2022","unstructured":"Bahmanyar M, Vakil MK, Al-Awsi GRL, Kouhpayeh SA, Mansoori Y, Mansoori B, et al. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment. BMC Cancer. 2022;22(1):1220. https:\/\/doi.org\/10.1186\/s12885-022-10320-0.","journal-title":"BMC Cancer"},{"key":"3762_CR244","doi-asserted-by":"publisher","unstructured":"Kaur K, Topchyan P, Jewett A. Supercharged Natural Killer (sNK) Cells Inhibit Melanoma Tumor Progression and Restore Endogenous NK Cell Function in Humanized BLT Mice. Cancers (Basel). 2025;17(15). https:\/\/doi.org\/10.3390\/cancers17152430.","DOI":"10.3390\/cancers17152430"},{"issue":"2","key":"3762_CR245","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1615\/CritRevImmunol.2023050618","volume":"43","author":"K Kaur","year":"2023","unstructured":"Kaur K, Jewett A, Supercharged NK. Cell-Based Immuotherapy in Humanized Bone Marrow Liver and Thymus (Hu-BLT) Mice Model of Oral, Pancreatic, Glioblastoma, Hepatic, Melanoma and Ovarian Cancers. Crit Rev Immunol. 2023;43(2):13\u201325. https:\/\/doi.org\/10.1615\/CritRevImmunol.2023050618.","journal-title":"Crit Rev Immunol"},{"issue":"2","key":"3762_CR246","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.4110\/in.2020.20.e14","volume":"20","author":"MH Shin","year":"2020","unstructured":"Shin MH, Kim J, Lim SA, Kim J, Kim S-J, Lee K-M. NK Cell-Based Immunotherapies in Cancer. Immune Netw. 2020;20(2):e14. https:\/\/doi.org\/10.4110\/in.2020.20.e14.","journal-title":"Immune Netw"},{"key":"3762_CR247","doi-asserted-by":"publisher","first-page":"1306534","DOI":"10.3389\/fimmu.2023.1306534","volume":"14","author":"W Zheng","year":"2023","unstructured":"Zheng W, Ling S, Cao Y, Shao C, Sun X. Combined use of NK cells and radiotherapy in the treatment of solid tumors. Front Immunol. 2023;14:1306534. https:\/\/doi.org\/10.3389\/fimmu.2023.1306534.","journal-title":"Front Immunol"},{"key":"3762_CR248","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3389\/fimmu.2020.01295","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liu Y. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. Front Immunol. 2020;11:1295. https:\/\/doi.org\/10.3389\/fimmu.2020.01295.","journal-title":"Front Immunol"},{"key":"3762_CR249","doi-asserted-by":"publisher","unstructured":"Leem G, Jang S-I, Cho J-H, Jo JH, Lee HS, Chung MJ et al. Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1\/2a Trial. Cancers (Basel). 2022;14(17). https:\/\/doi.org\/10.3390\/cancers14174229.","DOI":"10.3390\/cancers14174229"},{"issue":"1","key":"3762_CR250","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jcyt.2017.09.009","volume":"20","author":"L Li","year":"2018","unstructured":"Li L, Li W, Wang C, Yan X, Wang Y, Niu C, et al. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma. Cytotherapy. 2018;20(1):134\u201348. https:\/\/doi.org\/10.1016\/j.jcyt.2017.09.009.","journal-title":"Cytotherapy"},{"issue":"10","key":"3762_CR251","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557\u201375. https:\/\/doi.org\/10.1038\/s41568-022-00491-0.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3762_CR252","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"key":"3762_CR253","doi-asserted-by":"publisher","first-page":"1454427","DOI":"10.3389\/fimmu.2024.1454427","volume":"15","author":"H Park","year":"2024","unstructured":"Park H, Kim G, Kim N, Ha S, Yim H. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol. 2024;15:1454427. https:\/\/doi.org\/10.3389\/fimmu.2024.1454427.","journal-title":"Front Immunol"},{"key":"3762_CR254","doi-asserted-by":"publisher","unstructured":"Nassief G, Anaeme A, Moussa K, Mansour AN, Ansstas G. Recent Advancements in Cell-Based Therapies in Melanoma. Int J Mol Sci. 2024;25(18):9848. https:\/\/doi.org\/10.3390\/ijms25189848.","DOI":"10.3390\/ijms25189848"},{"key":"3762_CR255","doi-asserted-by":"publisher","unstructured":"Lian G, Mak TS-K, Yu X, Lan H-Y. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors. Int J Mol Sci. 2021;23(1):164. https:\/\/doi.org\/10.3390\/ijms23010164.","DOI":"10.3390\/ijms23010164"},{"issue":"7","key":"3762_CR256","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41423-025-01297-4","volume":"22","author":"Z Shen","year":"2025","unstructured":"Shen Z, Meng X, Rautela J, Chopin M, Huntington ND. Adjusting the scope of natural killer cells in cancer therapy. Cell Mol Immunol. 2025;22(7):699\u2013711. https:\/\/doi.org\/10.1038\/s41423-025-01297-4.","journal-title":"Cell Mol Immunol"},{"key":"3762_CR257","doi-asserted-by":"publisher","first-page":"104553","DOI":"10.1016\/j.critrevonc.2024.104553","volume":"205","author":"J-H Tao","year":"2025","unstructured":"Tao J-H, Zhang J, Li H-S, Zhou Y, Guan C-X. Nature killer cell for solid tumors: Current obstacles and prospective remedies in NK cell therapy and beyond. Crit Rev Oncol Hematol. 2025;205:104553. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104553.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3762_CR258","doi-asserted-by":"publisher","unstructured":"Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E et al. Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight. 2017;2(8):e91438. https:\/\/doi.org\/10.1172\/jci.insight.91438.","DOI":"10.1172\/jci.insight.91438"},{"issue":"5","key":"3762_CR259","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40257-025-00957-5","volume":"26","author":"KK Tsai","year":"2025","unstructured":"Tsai KK, Komanduri KV. Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma. Am J Clin Dermatol. 2025;26(5):733\u201345. https:\/\/doi.org\/10.1007\/s40257-025-00957-5.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"3762_CR260","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/ajh.27349","volume":"99","author":"S Tu","year":"2024","unstructured":"Tu S, Zhou L, Huang R, Zhou X, Yang J, He Y, et al. Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients. Am J Hematol. 2024;99(7):1437\u201340. https:\/\/doi.org\/10.1002\/ajh.27349.","journal-title":"Am J Hematol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03762-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:11:36Z","timestamp":1781842296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03762-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":260,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3762"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03762-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}